Low molecular weight heparin for pregnancy complications?

Thrombosis Research

Volumn 123, Issue SUPPL. 3, 2009, Pages

  Greer, I A ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ALLERGY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENETICS; HEMATOMA; HIGH RISK POPULATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MATERNAL HYPERTENSION; OSTEOPOROSIS; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SCREENING; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 59449099388     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0049-3848(09)70129-x     Document Type: Article

References (14)

1. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D., et al. Thrombophilia and pregnancy a systematic review procedure. Br J Haematol 132 (2006) 171-196
2. Lin J., and August P. Genetic thrombophilias and pre-eclampsia: a meta analysis. Obstet Gynecol 105 (2005) 182-192
3. Dudding T.E., and Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta analysis. Thromb Haemost 91 (2004) 700-711
4. Dudding T., Heron J., Thakkinstian A., Nurk E., Golding J., Pembrey N., et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta analysis. J Thromb Haemost 6 11 (2008) 1869-1875
5. Clark P., Walker I.D., Govan L., Wu O., and Greer I.A. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO (H) blood groups on haemorrhagic and thrombotic pregnancy complications. Br J Haematol 140 (2008) 236-240
6. Greer I.A., and Nelson-Piercy C. Low molecular weight heparins for thrombophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005) 401-407
7. Dolitzky M., Inbal A., Segel Y., Weiss A., Brenner B., and Carp H. A randomized study of thrombophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 86 (2006) 362-366
8. Brenner B., Bar J., Ellis M., Yarom I., and Yohai D. Samueloff A. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 84 (2005) 770-773
9. Brenner B., Hoffman R., Carp H., Dulitsky M., and Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the Live-Enox study. J Thromb Haemost 3 (2005) 227-229
10. Roger M.A., Paidas N., Claire M., Middeldorp S., Kahn S., Martinelli I., et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 112 (2008) 320-324
11. Middeldorp S. Thrombophilia and pregnancy complications: cause or association?. J Thromb Haemost 5 Suppl 1 (2007) 276-282
12. Clark P., Twaddle S., Walker I.D., Scott L., and Greer I.A. Cost effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 359 (2002) 1919-1920
13. Wu O., Robertson L., Twaddle S., Lowe G.D., Clark P., Greaves M., et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10 11 (2006) 1-110
14. Wu O., Robertson L., Twaddle S., Lowe G., Clark P., Walker I., et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 131 (2005) 80-90